Avita Medical Earnings Call Signals Cautious Momentum

Avita Medical Ltd ((RCEL)) has held its Q1 earnings call. Read on for the main highlights of the call.

Avita Medical’s latest earnings call struck a cautiously optimistic tone as management highlighted improving revenue, tighter cost control, and early traction from new products. Executives framed the quarter as a shift from stabilization to execution, while acknowledging ongoing margin pressure, modest cash reserves, and the ramp-up risks inherent in launching Cohealyx and PermeaDerm.

Revenue Growth and Building Momentum

Avita reported Q1 2026 revenue of about $19.3 million, its highest quarterly haul in the past year and up roughly 4% year over year. Sequentially, sales rose about 10% versus Q4 2025, and management said this momentum carried into April, signaling healthier underlying demand trends across the portfolio.

Operating Expense Discipline

Total operating expenses fell to $24.5 million, down 11% from the prior-year period as earlier cost-saving actions took hold. Management emphasized that the company now operates from a more efficient, right-sized cost base, better matched to its current commercial scale and supporting a more sustainable path toward profitability.

Narrowing Net Loss

Net loss improved to $10.6 million, or $0.35 per share, versus $13.9 million, or $0.53 per share, a year ago, an improvement of nearly 24% in dollar terms. The smaller deficit reflects both higher revenue and reduced spending, suggesting operating leverage is beginning to emerge even as Avita continues to invest in growth.

Gross Margin Strength With Mix Trade-Offs

Overall gross margin came in at 81.7%, down from 84.7% a year earlier, primarily due to inventory reserves and a heavier mix of newer, lower-margin products. Core RECELL gross margin remained robust at about 85%, and management stressed that Cohealyx and PermeaDerm still add incremental gross profit dollars despite their lower percentage margins.

Cohealyx Clinical Momentum

Interim data from the Cohealyx-I study showed a notable cut in time to graft readiness, roughly 20 days faster than benchmark cases. Median time to grafting was around 11 days, with some patients grafted within the first week, and investigators reported high satisfaction, helping drive early but promising clinical adoption.

RECELL Reimbursement and Product Expansion

All seven Medicare Administrative Contractors have now published payment rates for RECELL, helping utilization gradually recover as procedure economics stabilize. Avita is also expanding into smaller burns with the RECELL GO mini device, while recent regulatory clearances in Australia and New Zealand open additional geographic channels.

BARDA Partnership Validates Platform

A new long-term agreement with BARDA supports U.S. burn emergency preparedness and could generate up to $25.5 million under certain scenarios. The contract guarantees about $3.9 million over 10 years, or roughly $100,000 per quarter, providing modest recurring revenue and external validation of Avita’s scalability in a preparedness setting.

Improved Commercial Cadence and Visibility

Management highlighted a shift toward more frequent, smaller orders that better track product usage, especially among core burn centers and Tier 1 trauma accounts. This pattern is enhancing demand visibility, with Avita now running a weekly forecasting cadence that should support more consistent results and inventory planning.

Balance Sheet and Credit Facility Cushion

Avita ended the quarter with about $14.3 million in cash and marketable securities, a relatively modest buffer given its current burn rate. However, a new credit facility with Perceptive Advisors comes with more flexible covenants, including a trailing 12-month revenue test of $69 million that implies only about $15 million of revenue is needed in Q2 to stay compliant.

Margin Pressure From Mix and Reserves

The roughly three-point year-over-year decline in gross margin was largely attributed to inventory reserves and the rising contribution of early-stage products Cohealyx and PermeaDerm. While these offerings dilute the margin percentage in the near term, management argued that they are important to long-term growth and will benefit as scale improves.

Cash Burn and Seasonality Concerns

Net cash used in Q1 was approximately $9.9 million, a sizable draw relative to the company’s $14.3 million end-of-quarter cash and securities balance. Management pointed to timing and seasonality in cash receipts and said they expect a significant decrease in cash use during Q2, but investors will watch this metric closely.

Early-Stage Risk in New Product Launches

Cohealyx and PermeaDerm remain in the early adoption phase, with encouraging but still limited commercial traction to date. PermeaDerm’s performance is described as developing, and key supporting clinical data are expected later this year, underscoring the execution risk tied to scaling these franchises.

Reimbursement and Adoption Work Ahead

Despite reimbursement clarity from all seven MACs and an estimated 75% recovery in physician and hospital confidence, work remains to fully restore utilization. Management said it must still educate hospitals one by one and address roughly 55 to 60 centers in VAC status before RECELL adoption returns to its full potential footprint.

Guidance and Management Caution

Avita reaffirmed its full-year 2026 net revenue outlook of $80 million to $85 million, resisting the urge to raise guidance after a stronger-than-expected Q1. The company expects continued sequential growth into Q2, supported by increasing utilization in core burn and trauma accounts, but is signaling prudence about the durability of early momentum and the pace of new product uptake.

In sum, Avita appears to be shifting from repair mode to active execution, with rising revenue, leaner operations, and expanding clinical data supporting its wound-care portfolio. Investors, however, must weigh this early momentum against ongoing cash burn, margin pressure from mix, and the inherent uncertainty of scaling new technologies in a still-normalizing reimbursement environment.